Novel strategies in the thiopurine treatment of inflammatory bowel disease

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 4-6, 2010, Pages 267-277

  Almer, S ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Crohn's disease; inflammatory bowel disease; Thiopurines; treatment strategies; ulcerative colitis

Indexed keywords

ADALIMUMAB; ALLOPURINOL; AMINOSALICYLIC ACID; AUTOANTIBODY; AZATHIOPRINE; DRUG METABOLITE; GUANOSINE 5' MONOPHOSPHATE SYNTHETASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFLIXIMAB; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OXIDOREDUCTASE; PLACEBO; PREDNISONE; PRODRUG; THIOGUANOSINE; THIOINOSINE MONOPHOSPHATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTHRALGIA; BONE MARROW TOXICITY; CLINICAL TRIAL; CROHN DISEASE; DNA METHYLATION; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; INTESTINE RESECTION; LIVER BIOPSY; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MYALGIA; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; RELAPSE; REMISSION; REVIEW; STEROID THERAPY; TREATMENT INDICATION; TREATMENT PLANNING; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ANIMALS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; THIONUCLEOSIDES;

EID: 77953704202     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003729559     Document Type: Review

References (28)

1. Lindqvist, M.; Hindorf, U.; Almer, S.; Peterson, C. Thiopurines in inflammatory bowel disease-the role of pharmacogenetics and therapeutic drug monitoring. Current Pharmacogenomics 2006, 4, 285-300.
2. Prefontaine, E.; Sutherland, L.R.;Macdonald, J.K.; Cepoiu,M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2009, Jan 21(1): CD000067.
3. Markowitz, J.; Grancher, K.; Kohn, N.; Lesser, M.; Daum, F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.Gastroenterology 2000, 119, 895-902.
4. Peyrin-Biroulet, L.;Deltenre, P.;Ardizzone, S.;D'Haens, G.; Hanauer, S.B.;Herfarth, H.; Ĺemann, M.; Colombel, J.F. Azathioprine and 6-Mercaptopurine for the prevention of postoperative recurrence in Crohn's Disease: A meta-analysis. Am. J. Gastroenterol. 2009, 104, 2089-2096.
5. Hawthorne, A.B.; Logan, R.F.; Hawkey, C.J.; Foster, P.N.; Axon, A.T.; Swarbrick, E.T.; Scott, B.B.; Lennard-Jones, J.E. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305, 20-22.
6. Ardizzone, S.; Maconi, G.; Russo, A.; Imbesi, V.; Colombo, E.; Bianchi Porro, G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55, 47-53.
7. Hindorf, U.; Lindqvist, M.; Hildebrand, H.; Fagerberg, U.; Almer, S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol. Ther. 2006, 24, 331-342.
8. Hindorf, U.; Johansson, M.; Eriksson, A.; Kvifors, E.; Almer, S.H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol. Ther. 2009, 29, 654-661.
9. Almer, S.H.; Hjortswang, H.; Hindorf, U. 6-Thioguanine therapy in Crohn's disease-observational data in Swedish patients. Dig. Liver Dis. 2009, 41, 194-200.
10. Teml, A.; Schwab, M.; Hommes, D.W.; Almer, S.; Lukas, M.; Feichtenschlager, T.; Florin, T.; Seiderer, J.; Petritsch, W.; Bokemeyer, B.; Kreisel, W.; Herrlinger, K.R.; Knoflach, P.; Bonaz, B.; Klugmann, T.; Herfarth, H.; Pedarnig, N.; Reinisch, W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr. 2007, 119, 519-526.
11. de Boer, N.K.; Zondervan, P.E.; Gilissen, L.P.; den Hartog, G.; Westerveld, B.D.; Derijks, L.J.; Bloemena, E.; Engels, L.G.; van Bodegraven, A.A.; Mulder, C.J. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis. 2008, 40, 108-113.
12. Ĺemann, M.; Mary, J.Y.; Duclos, B.; Veyrac, M.; Dupas, J.L.; Delchier, J.C.; Laharie, D.; Moreau, J.; Cadiot, G.; Picon, L.; Bourreille, A.; Sobahni, I.; Colombel, J.F. Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130, 1054-1061.
13. Sandborn, W.J.; Rutgeerts, P.J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.R.; van der Woude, C.J.; Diamond, R.; Broussard, D.; Tang, K.L.; Colombel, J.F. One year data from the Sonic Study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology 2009, 136, Suppl 1, 751f.
14. de Boer, N.K.; Derijks, L.J.; Keizer-Garritsen, J.J.; Lambooy, L.H.; Ruitenbeek, W.; Hooymans, P.M.; van Bodegraven, A.A.; de Jong, D.J. Extended thiopurinemetabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. J. Clin. Pharmacol. 2007, 47, 187-191.
15. Vikingsson, S.; Carlsson, B.; Almer, S.H.; Peterson, C. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther. Drug Monit. 2009, 31, 345-350.
16. Neurath, M.F.; Kiesslich, R.; Teichgräber, U.; Fischer, C.; Hofmann, U.; Eichelbaum, M.; Galle, P.R.; Schwab, M. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin. Gastroenterol. Hepatol. 2005, 3, 1007-1014.
17. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 2003, 111, 1133-1145.
18. Dubinsky, M.C.; Lamothe, S.; Yang, H.Y.; Targan, S.R.; Sinnett, D.; Th́eorêt, Y.; Seidman, E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118, 705-713.
19. Hindorf, U.; Lyrenäs, E.; Nilsson, A.; Schmiegelow, K. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand. J. Gastroenterol. 2004, 39, 1105-1112.
20. Osterman, M.T.; Kundu, R.; Lichtenstein, G.R.; Lewis, J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130, 1047-1053.
21. de Boer, N.K.; Wong, D.R.; Jharap, B.; de Graaf, P.; Hooymans, P.M.; Mulder, C.J.; Rijmen, F.; Engels, L.G.; van Bodegraven, A.A. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am. J. Gastroenterol. 2007, 102, 2747-2753.
22. Hindorf, U.; Lindqvist, M.; Peterson, C.; Söderkvist, P.; Ström, M.; Hjortswang, H.; Pousette, A.; Almer, S. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.Gut. 2006, 55, 1423-1431. (Pubitemid 44476786)
23. Dubinsky, M.C.; Yang, H.; Hassard, P.V.; Seidman, E.G.; Kam, L.Y.; Abreu, M.T.; Targan, S.R.; Vasiliauskas, E.A. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122, 904-915.
24. Sparrow, M.P.; Hande, S.A.; Friedman, S.; Cao, D.; Hanauer, S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 2007, 5, 209-214.
25. Schaeffeler, E.; Fischer, C.; Brockmeier, D.; Wernet, D.; Moerike, K.; Eichelbaum, M.; Zanger, U.M.; Schwab, M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004, 14, 407-417.
26. Haglund, S.; Taipalensuu, J.; Peterson, C.; Almer, S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 2008, 65, 69-77.
27. Haglund, S.; Vikingsson, S.; Taipalensuu, J.; Coulthard, S.; Hindorf, H.; Danelius, M.; Peterson, C.; Almer, S.H. A "Skewed" thiopurine metabolite profile in IBD patients is not explained by variations in inosine-5-monophosphate dehydrogenase activity. Gastroenterology 2009, 136, Suppl 1, W1208.
28. Sparrow, M.P.; Hande, S.A.; Friedman, S.; Lim, W.C.; Reddy, S.I.; Cao, D.; Hanauer, S.B. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol. Ther. 2005, 22, 441-446.